Filing Flows › Guardant Health (GH) › R&D spending
Guardant Health (GH) R&D spending by quarter
Guardant Health's R&D spending was $101M in Q3 2026 (third quarter 2026), +4% from Q2 2026. Over the last 7 quarters it ranged from $87.4M (Q2 2025) to $101M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $101M | +4% | +12% |
| Q2 2026 | $96.5M | +6% | +10% |
| Q1 2026 | $91.0M | -7% | +3% |
| Q4 2025 | $98.3M | +9% | — |
| Q3 2025 | $90.0M | +3% | — |
| Q2 2025 | $87.4M | -1% | — |
| Q1 2025 | $88.5M | — | — |
Q3 2026 at a glance
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Guardant Health's R&D spending?
Guardant Health's R&D spending was $101M in Q3 2026 (third quarter 2026), +4% from Q2 2026.
How has Guardant Health's R&D spending changed?
Over the last 7 quarters it ranged from $87.4M (Q2 2025) to $101M (Q3 2026).